Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

Minocycline

"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."

DRUG

Placebo

"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."

Trial Locations (1)

21228

Maryland Psychiatric Research Center, Catonsville

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT01433055 - Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients | Biotech Hunter | Biotech Hunter